China Biologic Products, Inc. (CBPO.OB) to List Stock on NASDAQ
China Biologic Products, Inc. (CBPO), the largest non-state owned biopharmaceutical company in China, announced today the reception of approval to list its common stock on the NASDAQ. CBPO, through its majority-owned subsidiaries, constitutes a fully integrated biologic products company, with plasma collection, R&D, production, development, and commercial operations. With a well-established conduit into China’s top hospitals, the various plasma-based products made by CBPO are vital during medical emergencies, or are used for prevention and treatment. CBPO expects shares to begin trading on the NASDAQ tomorrow, Wednesday, Dec. 2, retaining the CBPO ticker. CEO of CBPO Mr. Chao Ming Zhao thanked…